Patents Assigned to Lumiphore, Inc.
-
Patent number: 11951188Abstract: The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.Type: GrantFiled: March 7, 2019Date of Patent: April 9, 2024Assignee: LUMIPHORE, INC.Inventors: David Tatum, Jide Xu, Darren Magda, Nathaniel Butlin
-
Patent number: 11691997Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.Type: GrantFiled: April 1, 2015Date of Patent: July 4, 2023Assignee: LUMIPHORE, INC.Inventors: Nathaniel G. Butlin, Darren Magda, Jide Xu
-
Patent number: 11603371Abstract: The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.Type: GrantFiled: March 25, 2019Date of Patent: March 14, 2023Assignee: LUMIPHORE, INC.Inventors: David Tatum, Jide Xu, Darren Magda, Nathaniel Butlin
-
Patent number: 11453652Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.Type: GrantFiled: November 15, 2013Date of Patent: September 27, 2022Assignee: LUMIPHORE, INC.Inventors: Darren Magda, Jide Xu, Nathaniel G. Butlin
-
Patent number: 10434186Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.Type: GrantFiled: December 21, 2015Date of Patent: October 8, 2019Assignee: LUMIPHORE, INC.Inventors: Nathaniel G. Butlin, Darren Magda, Jide Xu
-
Patent number: 10352938Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds comprise hydroxypyridinonyl moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability.Type: GrantFiled: February 25, 2016Date of Patent: July 16, 2019Assignee: LUMIPHORE, INC.Inventors: Nathaniel G. Butlin, Kenneth N. Raymond, Jide Xu, Anthony D'Aleo
-
Patent number: 10273256Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.Type: GrantFiled: June 22, 2018Date of Patent: April 30, 2019Assignee: LUMIPHORE, INC.Inventors: Nathaniel G. Butlin, Darren Magda, Jide Xu
-
Patent number: 10239878Abstract: The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.Type: GrantFiled: March 7, 2018Date of Patent: March 26, 2019Assignee: LUMIPHORE, INC.Inventors: David Tatum, Jide Xu, Darren Magda, Nathaniel Butlin
-
Patent number: 9914959Abstract: A new kit is provided for detecting or quantifying the amount of one or multiple nucleic acid targets in a biological sample, and a detection or quantification method using this kit. The present kit is constituted by a universal energy donor probe, a universal energy acceptor probe and a couple of adaptors.Type: GrantFiled: May 25, 2015Date of Patent: March 13, 2018Assignees: UNIVERSITE PARIS-SUD, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, LUMIPHORE INC.Inventors: Niko Hildebrandt, Zongwen Jin
-
Publication number: 20160221971Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.Type: ApplicationFiled: November 15, 2013Publication date: August 4, 2016Applicant: LUMIPHORE, INC.Inventors: Darren Magda, Jide Xu, Nathaniel G. Butlin
-
Patent number: 9273059Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds comprise hydroxypyridinonyl moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability.Type: GrantFiled: August 24, 2010Date of Patent: March 1, 2016Assignee: LUMIPHORE, INC.Inventors: Nathaniel G. Butlin, Kenneth N. Raymond, Jide Xu, Anthony D'Aleo
-
Patent number: 8507199Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.Type: GrantFiled: January 25, 2008Date of Patent: August 13, 2013Assignee: Lumiphore, Inc.Inventors: Nathaniel G. Butlin, Todd M. Corneillie, Jide Xu
-
Publication number: 20120214253Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds comprise hydroxypyridinonyl moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability.Type: ApplicationFiled: August 24, 2010Publication date: August 23, 2012Applicant: LUMIPHORE, INC.Inventors: Nathaniel G. Butlin, Kenneth N. Raymond, Jide Xu, Anthony D'Aleo
-
Publication number: 20120190012Abstract: The invention provides compositions and methods useful in DNA sequencing. In exemplary embodiments, a detectable label such as a luminescent macrocycle is used.Type: ApplicationFiled: April 6, 2011Publication date: July 26, 2012Applicant: LUMIPHORE, INC.Inventors: Nathaniel G. BUTLIN, Ga-Lai LAW, Christopher ANDOLINA
-
Publication number: 20110189088Abstract: The invention provides compounds such as chelating agents useful in chelating metal ions, particularly radionuclides, to provide metal ion complexes. The invention also provides methods of using the compounds and complexes of the invention, such as in therapeutic and diagnostic applications.Type: ApplicationFiled: December 23, 2010Publication date: August 4, 2011Applicant: Lumiphore, Inc.Inventors: Jide Xu, Nathaniel G. Butlin, Darren Magda
-
Publication number: 20080213780Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.Type: ApplicationFiled: January 25, 2008Publication date: September 4, 2008Applicant: Lumiphore, Inc.Inventors: Nathaniel G. Butlin, Todd M. Corneillie, Jide Xu